1,645
Views
13
CrossRef citations to date
0
Altmetric
Brief Reports

Inhibition studies of bacterial α-carbonic anhydrases with phenols

, , ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 666-671 | Received 15 Jan 2022, Accepted 01 Feb 2022, Published online: 09 Feb 2022
 

Abstract

The α-class carbonic anhydrases (CAs, EC 4.2.1.1) from the bacterial pathogens Neisseria gonorrhoeae (NgCAα) and Vibrio cholerae (VchCAα) were investigated for their inhibition by a panel of phenols and phenolic acids. Mono-, di- and tri-substituted phenols incorporating additional hydroxyl/hydroxymethyl, amino, acetamido, carboxyl, halogeno and carboxyethenyl moieties were included in the study. The best NgCAα inhibitrs were phenol, 3-aminophenol, 4-hydroxy-benzylalcohol, 3-amino-4-chlorophenol and paracetamol, with KI values of 0.6–1.7 µM. The most effective VchCAα inhibitrs were phenol, 3-amino-4-chlorophenol and 4-hydroxy-benzyl-alcohol, with KI values of 0.7–1.2 µM. Small changes in the phenol scaffold led to drastic effects on the bacterial CA inhibitory activity. This class of underinvestigated bacterial CA inhibitors may thus lead to effective compounds for fighting drug resistant bacteria.

Acknowledgements

CTS thank the Italian Ministry for University and Research (MIUR), project FISR2019_04819 BacCAD.

Disclosure statement

CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

The research program was also partially funded by a Purdue Institute for Drug Discovery Programmatic Grant (to D.P.F.) and NIH/NIAID 1R01AI148523 (to D.P.F.).